NASDAQ:CBIO - Catalyst Biosciences Stock Price, Forecast & News

Catalyst Biosciences trades on the NASDAQ under the ticker symbol "CBIO."

Catalyst Biosciences's stock reverse split on the morning of Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 10th 2017. An investor that had 100 shares of Catalyst Biosciences stock prior to the reverse split would have 7 shares after the split.

Catalyst Biosciences Inc (NASDAQ:CBIO) released its earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.01. View Catalyst Biosciences' Earnings History.

Catalyst Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Catalyst Biosciences.

1 brokers have issued twelve-month price objectives for Catalyst Biosciences' shares. Their forecasts range from $25.00 to $25.00. On average, they expect Catalyst Biosciences' stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 252.6% from the stock's current price. View Analyst Price Targets for Catalyst Biosciences.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Biosciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catalyst Biosciences.

Media coverage about CBIO stock has trended negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Catalyst Biosciences earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Catalyst Biosciences.

Catalyst Biosciences saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 561,100 shares, an increase of 52.5% from the December 15th total of 368,000 shares. Based on an average daily trading volume, of 490,000 shares, the short-interest ratio is currently 1.1 days. Currently, 5.1% of the company's shares are short sold. View Catalyst Biosciences' Current Options Chain.

Some companies that are related to Catalyst Biosciences include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Biosciences investors own include Baozun (BZUN), Celsion (CLSN), Synergy Pharmaceuticals (SGYP), Sarepta Therapeutics (SRPT), NovaBay Pharmaceuticals (NBY), Catalyst Pharmaceuticals (CPRX), Inovio Pharmaceuticals (INO), Achillion Pharmaceuticals (ACHN), Onconova Therapeutics (ONTX) and Amarin (AMRN).

Shares of CBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CBIO stock can currently be purchased for approximately $7.09.

Catalyst Biosciences has a market capitalization of $85.36 million and generates $10,000.00 in revenue each year. The biopharmaceutical company earns $-30,060,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Catalyst Biosciences employs 21 workers across the globe.View Additional Information About Catalyst Biosciences.

The official website for Catalyst Biosciences is http://www.catalystbiosciences.com/.

Catalyst Biosciences' mailing address is 611 GATEWAY BLVD. SUITE 710, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-871-0761 or via email at [email protected]